Search results for "Plasminogen"

showing 10 items of 142 documents

Enhancement of Wound Healing in Normal and Diabetic Mice by Topical Application of Amorphous Polyphosphate. Superior Effect of a Host⁻Guest Composite…

2017

The effect of polyphosphate (polyP) microparticles on wound healing was tested both in vitro and in a mice model in vivo. Two approaches were used: pure salts of polyphosphate, fabricated as amorphous microparticles (MPs, consisting of calcium and magnesium salts of polyP, “Ca–polyp-MPs” and “Mg–polyp-MPs”), and host–guest composite particles, prepared from amorphous collagen (host) and polyphosphate (guest), termed “col/polyp-MPs”. Animal experiments with polyP on healing of excisional wounds were performed using both normal mice and diabetic mice. After a healing period of 7 days “Ca–polyp-MP” significantly improved re-epithelialization in normal mice from 31% (control) to 72% (polyP micr…

0301 basic medicinecollagenMaterials sciencePolymers and PlasticsPAI-1chemistry.chemical_elementpolyphosphate; microparticles; delayed wound healing; collagen; PAI-1; re-epithelialization; diabetic mice02 engineering and technologymacromolecular substancesCalciumdiabetic miceArticlelcsh:QD241-44103 medical and health scienceschemistry.chemical_compoundlcsh:Organic chemistryIn vivootorhinolaryngologic diseasesre-epithelializationneoplasmsmicroparticlesPolyphosphateDiabetic mousepolyphosphateGeneral Chemistry021001 nanoscience & nanotechnologyMolecular biologyIn vitrodigestive system diseases3. Good healthAmorphous solid030104 developmental biologysurgical procedures operativechemistry0210 nano-technologyWound healingPlasminogen activatordelayed wound healingPolymers
researchProduct

Micro-RNA profile and proteins in peritoneal fluid from women with endometriosis: their relationship with sterility.

2018

Objective: To define the microRNA (miRNA) profile and its relationship with cytokines content in peritoneal fluid (PF) from endometriosis patients. Design: Case-control study. Setting: University hospital, research institute. Patient(s): One hundred twenty-six women with endometriosis (EPF) and 45 control women (CPF). Main Outcomes Measure(s): MiRNA arrays were prepared from six EPF and six CPF. Quantitative reverse transcription-polymerase chain reaction validation of nine selected miRNAs (miR-29c-3p, -106b-3p, -130a-3p, -150-5p, -185-5p, -195-5p, -451a, -486-5p, and -1343-5p) was performed. Vascular endothelial growth factor-A (VEGF-A), thrombospondin-1 (TSP-1), urokinase plasminogen acti…

0301 basic medicineendometriosisAdultProteomicsMMP3AngiogenesisEndometriosisEndometriosisEnzyme-Linked Immunosorbent AssayAndrology03 medical and health sciences0302 clinical medicinePregnancymedicineAscitic FluidHumansAngiogenic ProteinsMacrophage inflammatory proteinOligonucleotide Array Sequence Analysis030219 obstetrics & reproductive medicinemicroRNAbusiness.industryPeritoneal fluidGene Expression ProfilingObstetrics and GynecologyInterleukinProteinsMiddle Agedmedicine.diseaseFold changeMicroRNAs030104 developmental biologyperitoneal fluidFertilityReproductive MedicineinflammationCase-Control StudiesCytokinesFemaleAngiogenesisInflammation MediatorsbusinessTranscriptomePlasminogen activatorInfertility FemaleFertility and sterility
researchProduct

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme …

2020

Bradykinin (BK)-mediated angioedema (AE) states are rare acquired or hereditary conditions involving localized edema of the subcutaneous and submucosal tissues. Citrated plasma from healthy volunteers or patients with hereditary angioedema (HAE) with normal level of C1-inhibitor (C1-INH) was used to investigate pathways of BK formation and breakdown relevant to AE physiopathology. The half-life of BK (100 nM) added to normal plasma was 34 s, a value that was increased ~12-fold when the angiotensin converting enzyme (ACE) inhibitor enalaprilat (130 nM) was added (enzyme immunoassay measurements). The BK half-life was similarly increased ~5-fold following 2 daily oral doses of enalapril malea…

0301 basic medicinemedicine.medical_specialtykallikreinsPlasminBradykininTissue plasminogen activator03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineB2 receptorsOriginal ResearchplasminFactor XIIlcsh:R5-920tissue plasminogen activatorAngioedemabiologyhereditary angioedema with normal C1 inhibitor levelAngiotensin-converting enzymeGeneral MedicineKallikreinmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemchemistryHereditary angioedemabiology.proteinMedicinemedicine.symptombradykininlcsh:Medicine (General)medicine.drugFrontiers in Medicine
researchProduct

Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels

2016

Background Hereditary angioedema with normal C1 inhibitor levels (HAE-N) is associated with a Factor XII mutation in 30% of subjects; however, the role of this mutation in the pathogenesis of angioedema is unclear. Objective We sought evidence of abnormalities in the pathways of bradykinin formation and bradykinin degradation in the plasma of patients with HAE-N both with and without the mutation. Methods Bradykinin was added to plasma, and its rate of degradation was measured by using ELISA. Plasma autoactivation was assessed by using a chromogenic assay of kallikrein formation. Plasminogen activator inhibitors (PAIs) 1 and 2 were also measured by means of ELISA. Results PAI-1 levels varie…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentImmunologyBradykinin030204 cardiovascular system & hematologyArticleC1-inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineFibrinolysismedicineImmunology and AllergyFactor XIIAngioedemabiologybusiness.industryKallikreinmedicine.disease030104 developmental biologyEndocrinologychemistryPlasminogen activator inhibitor-1Hereditary angioedemabiology.proteinmedicine.symptombusinessJournal of Allergy and Clinical Immunology
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct

Systematic Analysis of Combined Thrombolysis Using Ultrasound and Different Fibrinolytic Drugs in an in Vitro Clot Model of Intracerebral Hemorrhage.

2021

Adequate removal of blood clots by minimally invasive surgery seems to correlate with a better clinical outcome in patients with intracerebral hemorrhages (ICHs). Moreover, neurotoxic effects of recombinant tissue plasminogen activator have been reported. The aim of this study was to improve fibrinolysis using an intra-clot ultrasound application with tenecteplase and urokinase in our established ICH clot model. One hundred thirty clots were produced from 25 or 50 mL of human blood, incubated for different periods and equipped with drainage, through which an ultrasound catheter was placed in 65 treatment clots for 1 h, randomly allocated into three groups: administration of ultrasound, admi…

Acoustics and UltrasonicsMechanical Thrombolysismedicine.medical_treatmentUltrasonic TherapyBiophysicsTenecteplase030204 cardiovascular system & hematologyIn Vitro Techniques03 medical and health sciences0302 clinical medicineFibrinolytic AgentsFibrinolysismedicineHumansRadiology Nuclear Medicine and imagingThrombolytic TherapyCerebral HemorrhageIntracerebral hemorrhageUrokinaseRadiological and Ultrasound Technologybusiness.industryUltrasoundThrombosisThrombolysismedicine.diseaseCombined Modality TherapyUrokinase-Type Plasminogen ActivatorIn vitroCatheterAnesthesiaTenecteplasebusiness030217 neurology & neurosurgerymedicine.drugUltrasound in medicinebiology
researchProduct

Hemostatic function in young subjects with central obesity: relationship with left ventricular function.

1995

This study was designed to evaluate coagulation and fibrinolysis activity and their relationship with left ventricular function in young obese subjects with central fat distribution. We assessed coagulation and fibrinolysis activity by evaluation of factor VII activity, fibrinogen and plasminogen, plasminogen activator inhibitor (PAI), and tissue plasminogen activator antigen basally (tPA1) and after venous occlusion (tPA2). These measures were evaluated in young (< 40 years) obese subjects with central fat distribution (n = 19) and in comparable lean subjects (n = 20). Blood glucose, triglycerides, total and high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) A1 and apo B, fas…

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenVentricular Function LeftSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundEndocrinologyWaist–hip ratioInternal medicineFibrinolysismedicineHumansInsulinObesityHemostatic functionBlood CoagulationApolipoproteins ATriglyceridesApolipoproteins BHemostasisbiologybusiness.industryCholesterolCholesterol HDLFibrinogenCentral obesity Hemostatic function left ventricular functionPlasminogenFactor VIISettore MED/11 - Malattie Dell'Apparato CardiovascolarePlasminogen InactivatorsEndocrinologychemistrybiology.proteinBody ConstitutionRegression AnalysisFemalebusinessPlasminogen activatormedicine.drugLipoproteinMetabolism: clinical and experimental
researchProduct

Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.

2000

In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome, a multicenter double-blind placebo controlled, parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance. These patients had elevated PAI activity and antigen and t-PA antigen levels at rest and after venous occlusion. Gemfibrozil reduced plasma triglyceride levels (P0.001), whereas it increased free fatty acids (P0.05) and high density lipoprotein cholesterol levels (P0.05). In those patients reaching normalization of plasma triglyceride levels (triglyceride reductionor =50%) (n=15), insulin levels (P0.05) as well as the …

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentFatty Acids NonesterifiedPlaceboFibrinogenInsulin resistanceDouble-Blind MethodInternal medicinemedicineGemfibrozilHumansInsulinAgedHypolipidemic AgentsHypertriglyceridemiaHemostasisbusiness.industryT-plasminogen activatorInsulinHypertriglyceridemiaParallel studyGlucose Tolerance TestMiddle Agedmedicine.diseaseEndocrinologyGemfibrozilInsulin ResistanceCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

PAI-1 Levels are Related to Insulin Resistance and Carotid Atherosclerosis in Subjects with Familial Combined Hyperlipidemia

2017

Familial combined hyperlipidemia (FCH) is a primary atherogenic dyslipidemia with insulin resistance and increased cardiovascular risk. Plasminogen activator inhibitor type 1 (PAI-1) and myeloperoxidase (MPO) activity are associated with proinflammatory and atherothrombotic risk. Our aim was to study the role played by PAI-1 and MPO activity in the carotid atherosclerosis prevalence in FCH subjects. 36 FCH unrelated subjects (17 women) were matched by age and body weight with 36 healthy normolipidemic subjects (19 female). Blood lipids, glucose, insulin, insulin resistance (homeostasis model assessment (HOMA)), MPO, and PAI-1 were determined in both groups. Carotid intima media thickness (…

AdultCarotid Artery DiseasesMale0301 basic medicinemedicine.medical_specialtyWaistmedicine.medical_treatmentHyperlipidemia Familial CombinedBlood lipids030204 cardiovascular system & hematologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicinePlasminogen Activator Inhibitor 1medicineHumansPeroxidasebiologybusiness.industryInsulinGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyEndocrinologyIntima-media thicknessCase-Control StudiesMyeloperoxidasebiology.proteinFemaleInsulin ResistanceMetabolic syndromebusinessBody mass indexJournal of Investigative Medicine
researchProduct

Inflammatory markers and cardiovascular risk in the metabolic syndrome

2011

Elevated blood glucose, obesity, high blood pressure, elevated triglycerides and low high density lipoprotein (HDL) cholesterol are well accepted risk factors in the development of coronary artery disease. Clustering of at least three of these factors in an individual is defined as metabolic syndrome (MetS). Obesity is a central pathological mechanism in the disease and it is expected that the incidence of this condition will increase dramatically within the next years. The visceral adipose tissue is not only an energy depot but also an endocrine organ which produces a large number of bioactive molecules, the so called adipokines. In the setting of obesity, the over-production of proinflamm…

AdultLeptinRiskAdolescentAngiotensinogenAdipokineAdipose tissueDiseaseIntra-Abdominal FatBioinformaticsCoronary artery diseasePathogenesisInsulin resistancePlasminogen Activator Inhibitor 1medicineHumansResistinObesityLife StyleChemokine CCL2InflammationMetabolic SyndromeInterleukin-6Tumor Necrosis Factor-alphabusiness.industryAtherosclerosisPrognosismedicine.diseaseObesityPlaque AtheroscleroticCardiovascular DiseasesAdiponectinEndothelium VascularInsulin ResistanceMetabolic syndromebusinessBiomarkersFrontiers in Bioscience
researchProduct